Jürgen Harter

I just published UK’s tryst with AI. This is an essay on what will it take for the UK to be another AI superpower and how can it better work together with US and rest of anglosphere to be at the forefront of technology. #artificialintelligence #AI #UK https://lnkd.in/gAkKFzg7

3

Our recent industry meeting inspired me to share my experience with the clinical trials budget and contract process. As always I try to provide some recommendations on how we can improve the process. At the end of the day our patients will be the winners if we can set up clinical trials much quicker. It is always good to have that in mind! #clinicaltrials #budget #contract #UK

4

💡 Want to understand the UK landscape and influence future #funding, #policy and #infrastructure in intracellular drug delivery? 💉 Calling on my UK network to participate in this online workshop on 14th May 2024 (10am-12pm) if you have an interest in advancing innovation in intracellular drug delivery. Our Intracellular Drug Delivery Centre is making great progress, but we want to find out what we need to do next to support the sector and have teamed up with Innovate UK and Innovate UK Business Connect to help find out! ❓ Who should attend? Representatives from industry, academia and supporting organisations working in this space. You might be a drug developer with specific delivery needs that current approaches can’t meet, or working to develop new technologies that provide advantages over current technologies. We aim to understand the breadth of innovative technologies being developed in the UK and identify those which have potential to address current clinical and commercial challenges. ❓ Why attend? ✔ Ensure that the barriers and challenges that you as an individual or organisation are facing are considered in future funding and policy decisions. ✔ Enhance your understanding of current intracellular drug delivery landscape, unmet needs and opportunities. ✔ Hear from others working in the space. ✔ Find out about public infrastructure that can support your technology or drug development. Sign up here 🔗 https://lnkd.in/eQUvp5-A Yvonne Perrie MBE Sarah Brockbank Robin Shattock Neill Liptrott CPI Medicines Discovery Catapult Brendan Fish Dave Tudor Julie Anderson Emily Port Owen Burbidge Hareklea Markides Rachel Harris Sarah Goulding Mark Talford #Pharmaceutical #IntracellularDrugDelivery #NewTechnologies #DrugDelivery #LNP #mRNA #oligos #TMMCOP #oligonucleotides #LetsInnovateTogether #Innovation

58

9 Comments

Thoughts on this? >> Dotmatics and Databricks Partner to Advance Scientific Intelligence in Life Sciences >> Comment below! >>> lqventures.com #IoT #industry40 #AI #healthtech #mhealth

1

🚨New #biotech policy proposals in Germany: the German national strategy for gene and cell therapies is intended to boost Germany's role in gene and cell therapies (GCT) in Europe. This Covington & Burling LLP blog outlines its key elements: https://okt.to/iO3oyv

4

Whenever I must read something with or about AI - and there is currently a lot of marketing around it, please note that the REGULATION (EU) 2024/1689 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 13 June 2024 - (Artificial Intelligence Act) is in operations since 1. August 2024. This regulation applies to any system / machine / equipment supplier in the European Union and to suppliers and service providers outside of EU selling AI in EU. If we want to use AI in GXP (MedDev, GMP, CGMP in EU, GLP, GCP, GDP, GVP) this regulations applies and corresponding harmonized regulations. In addition, applications must be validated in GXP. https://lnkd.in/e_YKq_vT

22

2 Comments

"How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons" A paper from the Boston Consulting Group (BCG) published in Elsevier's Drug Discovery Today As far as i know, this is the first paper looking (holistically) at "AI-developed" drug vs drugs developed using a traditional workflow. 🌟 "In Phase I we find AI-discovered molecules have an 80–90% success rate" -> much higher than industry average 🌟 "In Phase II the success rate is $40%, albeit on a limited sample size, comparable to historic industry averages" It's still too early to judge, but it's good to have this paper to clarify what are the metrics as of 2024

100

17 Comments

China’s 15% share of world’s clinical trials in 2023 remains less than that of W Europe at 25% and N America at 23%, however, this represents an increase of 57% since 2019. During the same period the proportion of trials being conducted in W Europe declined by 21% and E Europe’s share declined by 33%. The proportion of trials being run in N American increased by 17% from 2019 to 2023.

10

Interesting new paper in Nature Reviews Drug Discovery on R&D costs and R&D effectiveness across the drug majors. But as far as I can see, R&D costs are calculated in way that does not reconcile with what is implied by company accounts (which would give costs that are maybe >= 2x higher). If so, the "R&D Productivity Ratio" (NPV of profits from R&D / NPV of R&D investment) is rather flattering. Paper is here: https://lnkd.in/djAGUuZU

98

12 Comments

Three critical databases (CSD, ChEMBL, PDBe) for drug discovery are now interlinked. https://lnkd.in/ed3FFqG6

92

4 Comments

European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events Bagsværd, Denmark, 25 July 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Wegovy® (semaglutide 2.4 mg) label to reflect data from the SELECT cardiovascular outcomes trial, demonstrating a risk reduction of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with established cardiovascular disease (CVD) and either overweight or obesity (initial BMI ≥27 kg/m2) without diabetes.

10

Sharing some fresh survey results run by Daniel Erlanson, an industry thought leader in #fragment based drug discovery, who also keeps a blog on #practicalfragments. It is very interesting to know that X-ray crystallography is still the dominant working horse for fragment lead finding for innovative small molecule drug discovery, in the face of #AI and many other emerging tools. https://lnkd.in/gaMByTci #FBDD, #FBLD, #SBDD #XRay #crystallography #CryoEM #SPR #TSA (#DSF) #CADD, #MS (#ASMS), #FragmentLibrary #Screening #CrystalSoaking - all are flagship service areas at Viva Biotech

8

1 Comment

Here’s an interesting publication detailing how trial efficiency can reshape early-stage development in #biotech... In Phase I studies, every decision affects the development pathway, making trial design and timing critical. By introducing flexibility into these early phases, clinical teams can meet complex study demands without compromising on speed or quality—a balance essential in today’s fast-paced therapeutic field. With streamlined processes, from recruitment through data collection, biotech R&D professionals can better allocate resources, achieve reliable results, and move confidently toward later stages of development. #BiotechR&D #BioTech #BioPharm #EarlyStageDevelopment #ClinicalTrials #TrialEfficiency #DrugDevelopment

3

Great step forward in deploying an enhanced LLM based framework in predicting protein-protein interactions opening up future possibilities for drug discoveries, better understanding of the biological processes and related domains #llm #computationalbiology #druginteractions

17